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Abstract
We aimed to answer the question whether the decreased expression of protein kinase C (PKC) isoenzymes in the peripheral blood
mononuclear cells (PBMC) of patients with systemic lupus erythematosus (SLE) is inherited or not. For this reason we examined
the expression of PKC isoenzymes in a European white girl with acute SLE and in her healthy mother and father simultaneously in
summer and winter during one year using western blotting and densitometry. We found that in the father the expression of PKC
isoenzymes did not differ from that of eight healthy controls included women and men. However, in the “SLE-free”mother and in
the patient arrived in July with acute symptoms of lupus, the expression of PKC isoenzymes showed a season dependent undulation
in parallel. Namely, in summer the expression values were significantly lower, in winter they were significantly higher than those in
the controls. Thus, the decreased expression of PKC isoenzymes in the PBMC of SLE patient is not a disease specific marker; it
appears also in her lupus free mother. This phenomenon may be due to a season dependent female genetic background. However,
the low PKC levels in summer can still decrease further the low production of IL-2 in T cells of lupus patients augmenting the
existing AP-1 defects. This is the first report on the season and female dependent inherited changing of PKC expression in a
European white patient with SLE and her mother. Further studies are needed to confirm these findings in other populations.
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Introduction
Earlier, our group described the decreased expression of sev-
eral protein kinase C (PKC) isoenzymes both in monocytes (ε,
δ, η, ξ) and T cells (β, ε, δ, η, θ, ξ) of systemic lupus erythe-
matosus (SLE) patients consisting of white European women
in 90%; additionally, we also reported the elevating and re-
storing effects of glucocorticosteroid (GCS) treatment in vivo
and in vitro [1]. However, it remained obscure whether these
PKC impairments were inherited or acquired. To answer these
questions, we have got an exceptional chance to investigate a
European white family where the expression of PKC
isoenzymes could be tested simultaneously in the peripheral
blood mononuclear cells (PBMC) of healthy parents and the
daughter with fresh acute symptoms of severe SLE in different
seasons during one year. Their results were compared to the
group of 8 healthy European white control subjects.
Materials and Methods
The Patient and her Parents
The 20-year-old girl arrived in July (summer I) with some
purpuras on the leg, maculopapular rash and livedo reticularis,
oedema around the eyes and Raynaud’s phenomenon. White
blood cell count was 3530 cells/mm3, platelet count was
79,000 cells/mm3. The autoantibody profile showed anti-
nuclear antibody (ANA) positivity in 1:160 serum dilution
(homogenous pattern), and an increased level of anti-dsDNA
antibodies (74.1 versus 18 IU/ml). In addition, anti-platelet
antibody positivity, lower complement factor 4 level (0.09 g/
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l), and anti-Epstein-Barr virus serum IgG positivity were dem-
onstrated. Liver and renal tests were normal without protein-
uria. The SLE was diagnosed according to the criteria of
SLICC group based on the presence of photosensitivity,
maculopapular rash, leukopenia, thrombocytopenia, ANA,
anti-dsDNA positivity, representing an SLE Disease Activity
Index (SLEDAI) value of 14. The therapy started with
0.5 mg/kg of methylprednisolone (MP) (32 mg in total) and
250 mg of hydroxychloroquine (HC). The dose of MD was
gradually reduced to 8 mg until September, however the
250 mg of HC was continued.
The patient’s family history was negative for any autoim-
mune diseases; the 40-year-old healthy mother was still before
menopause and working as hairdresser. The healthy 41-year-
old father only with an abnormal glucose tolerance was work-
ing as truck driver. The 8-year-old younger brother was also
healthy. The family belongs to the Europeanwhite population.
In September, at the second visit of patient taking MP and
HC, the clinical state improved remarkably (SLEDAI was 5)
but the platelet cell count was still low (20,000 cells/mm3)
without any bleeding complications. Therefore, the dose of
MP was increased, HC remained and additionally azathio-
prine (AZA) was introduced (48 mg of MP + 250 mg of
HC + 150 mg of AZA). In December (in winter), at the third
visit, the dose of MP was reduced to 8 mg, HC and AZA
therapies were continued. The platelet count was already ele-
vated (112,000 cells/mm3) and SLEDAI was 8. In July, at the
fourth visit (in summer II), the clinical state improved further
(SLEDAI was 3), the platelet count became 196,000 cells/
mm3 and 8 mg of MP was continued together with 250 mg
of HC, while AZA treatment was stopped. The laboratory
tests still showed ANA and anti-dsDNA positivity (60.9 IU/
ml). Now, the patient has no clinical symptoms and receives
8 mg MP and 250 mg HC as maintenance therapy.
In December and the following July (summer II), the serum
levels of three thyroid hormones free thyroxine (FT4), free
triiodine-thyronine (FT3) and thyroid stimulating hormone
(TSH) were measured in the patient.
All three members of family gave a written consent
confirming their readiness to take part in this study and permit
to publish the results.
The Group of Healthy Controls
We enrolled 6 women (range of age: 21–43 years) and 2 men
(22 and 42 years old) who were chosen actually at the various
visit times of patient and mother.
Determination of PKC Isoenzymes in PBMC
PBMC were isolated by Ficoll (Sigma-Aldrich, USA) gradi-
ent centrifugation. The expression of PKC isoenzymes were
evaluated using western blotting and densitometry. Human β-
actin served as an endogenous internal control.
Statistical Analysis
Using SPSS 20 program, the numeric data of densitometry
were analysed and compared by Wilcoxon Signed-Rank
(non-parametric) test. Changes representing values of
p < 0.05 were regarded as statistically significant.
Results
Season Dependent Changes in the Expression of PKC
Isoenzymes in PBMC of SLE Patient, in her Parents
and Three Healthy Controls
Figure 1a demonstrates that at the first visit of the whole fam-
ily in July (summer I), the expression of all PKC isoforms (α,
β, δ, ε, η, θ) in the PBMC of healthy father was equally
strong, and did not differ from the intensity of β-actin. On
the other hand, the expression of isoenzymes was decreased
remarkably both in the lupus patient and her healthy mother
compared to the values of β-actin and the father’s results. For
September, the intensive MP therapy elevated and almost re-
stored the PKC levels, and resulted in a great improvement in
the clinical state of patient.
However, in December (winter), both in the patient
(treated with MP, HC and AZA) and her “SLE-free”
healthy mother without any medication, the expression
of the PKC isoenzymes elevated remarkably compared
to the values of “female control 1” (28-year-old
European white woman) (Fig. 1b).
Whereas in the following summer (summer II), the PKC
values of both the patient (taking MP, HC and AZA) and her
mother were lower again than those of “female control 4” (22-
year-old European white woman) and “female control 5” (41-
year-old European white woman) (Fig. 1c).
Numeric Data of Densitometry on the Expression
of PKC Isoenzymes in PBMC of the Family and Healthy
Controls
Table 1 presents all the numeric data of densitometry on the
expression of PKC isoenzymes in PBMC of the family
followed up for one year. In the data of the first visit in July
(summer I), then in September, the values of father’s densi-
tometry were regarded as 1.0 and the data of “mother” and
“patient” were compared to them and to their internal control,
β-actin. Later, in the further simultaneous studies on the cells
of “mother” and “patient”, the data of densitometry were sta-
tistically compared to the average of 8 subjects forming the
“group of healthy controls”. It was a striking surprise at the
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first visit that in the PBMC of healthy mother, the expression
of each PKC isoenzymes showed not only significantly lower
values than those in the healthy father and healthy controls
(0.09 + 0.23 versus 1.04 + 0.24; p < 0.05), but they were even
lower than those in her sick daughter (0.09 + 0.23 versus
0.33 + 0.27). In the patient, we recognized a similar pattern
what we published earlier [1] showing significant decrease in
the expression of various PKC isoenzymes (0.33 + 0.27 ver-
sus 1.04 + 0.27; p < 0.05), and the significant, almost total
restoring effect of MP (0.88 + 0.64 versus 0.33 + 0.27
Table 1 Numeric data of densitometry on the expression of PKC isoenzymes tested by western-blotting analysis in the peripheral blood mononuclear
cells of family members followed up for one year and in the healthy controls
Seasons PKC Father Mother Daughter SLE Daughter SLE treated Controls (n = 8)
Summer 1 α 1.00 0.00 0.27 0.90 1.11
β 1.00 0.00 0.07 0.50 1.11
δ 1.00 0.00 0.66 0.98 0.88
η 1.00 0.35 0.12 0.21 0.79
ε 1.00 0.20 0.61 2.20 1.51
θ 1.00 0.00 0.29 0.58 0.84
Average ± SD „A”
1.00
„B″
0.09 ± 0.23
„C″
0.33 ± 0.27
„D”
0.89 ± 0.64
„E”
1.04 ± 0.27
Winter α 2.60 2.80 1.11
β 1.44 1.20 1.11
δ 1.70 1.63 0.88
η 1.54 2.10 1.51
ε 1.05 0.66 0.79
θ 0.98 0.50 0.84
Average ± SD „F″
1.56 ± 0.59
„G”
1.48 ± 0.88
„E”
1.04 ± 0.27
Summer 2 α 0.63 0.85 1.11
β 0.13 0.16 1.11
δ 0.90 1.34 0.88
η 0.72 0.74 1.51
ε 0.09 0.30 0.79
θ 0.11 0.09 0.84
Average ± SD „H″
0.43 ± 0.36
„I″
0.58 ± 0.48
„E”
1.04 ± 0.27
Significant differences (p < 0.05) were found between B-E, C-E, C-D, F-E, G-E, H-E and I-E values
Fig. 1 The representative images of western-blotting analysis on the
expression of PKC isoenzymes in the peripheral blood mononuclear
cells of (a) patient with SLE and in the healthy parents tested in
summer I; (b) patient with SLE, in the mother and in a healthy control
tested in winter and (c) patient with SLE, in the mother and two healthy
controls tested in summer II
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p < 0.05). However, at the following visit in December (win-
ter), each PKC level, both in the mother and patient, increased
significantly compared to the values of healthy controls
(mother: 1.53 + 0.69; patient: 1.48 + 0.88; versus controls:
1.04 + 0.27; p < 0.05). On the other hand, in the following
July (summer II), the PKC levels were significantly decreased
again in both subjects, in the mother: 0.43 + 0.36; in the
patient (taking 8 mg of GCS + HC): 0.58 + 0.48 versus in
the controls: 1.04 + 0.27 (p < 0.05).
Changes in SLEDAI Values, Serum Levels of Thyroid
Hormones along with the MP Treatment of SLE
Patient during the Study
In Table 2, we summarized the changes in SLEDAI values of
patient and doses ofMPwith other immunosuppressive drugs.
Moreover, we also compared the serum levels of three thyroid
hormones in December and following July. The three hor-
mones, TSH, FT4 and FT3 regulating the seasonal adaptation,
showed slightly higher concentrations in winter than in sum-
mer suggesting a moderate suppression of gonadotropin se-
cretion. However, in summer the situation was inversed, the
decreased thyroid hormone levels might involve an elevated
gonadotropin secretion [2].
Discussion
This is the first report on the “season and GCS and thyroid
hormone dependent changing of PKC isoenzymes as a special
phenomenon of female genetic background” in the mononu-
clear cells of a European white female patient with newly
diagnosed acute SLE and in her lupus free mother.
Nevertheless, this special genetic background is not sufficient
alone to cause SLE yet. Still other pathologic hits may be also
required to induce and complete the disease. However, pre-
sumably in white female patients with lupus in summer, the
decreased expression of PKC isoenzymes can lead to a state
diminishing further the basically low production of interleukin
(IL)-2 in T cells augmenting the existing defect in the function
of activating protein-1 (AP-1) via the extracellular signal-
regulated kinase (ERK)1/2 [3, 4] and other AP-1 related path-
ways [5, 6], or the weak effect of PKC θ in alternative splicing
processes regulating gene expressions during T cell activation
[7]. In order to verify the wider existence and distribution of
this phenomenon, still further comparisons are needed in dif-
ferent genders [8, 9], countries and continents [10]. In addi-
tion, further genetic mapping of this family would be of worth
excluding any splicing or other variations.
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